- Market Capitalization, $K 7,509,205
- Shares Outstanding, K 351,884
- Annual Sales, $ 8,380 M
- Annual Income, $ -4,148,000 K
- 60-Month Beta 0.85
- Price/Sales 0.88
- Price/Cash Flow 1.70
- Price/Book 2.74
|Period||Period Low||Period High||Performance|
| || |
-1.20 (-5.13%)since 09/16/19
| || |
-1.00 (-4.32%)since 07/16/19
| || |
-3.75 (-14.47%)since 10/16/18
Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.
Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela....
Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.
Is (BHC) Outperforming Other Medical Stocks This Year?
Let's see if Bausch Health Cos (BHC) stock is a good choice for value-oriented investors right now from multiple angles.
Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.
Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.
|Bausch Health Companies Inc|
|Pharmaceutical Vaneck ETF|
|US Innovative Healthcare Ishares Evolved ETF|
|Invesco Developed Ex-US ETF|
|Schwab Fundamental Intl Large Company|
|Schwab Intl Equity ETF|